A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe Disease

Inclusion Criteria: * The participant's parent/legal guardian was willing and able to provide signed informed consent. * The participant might be less than or equal to 12 months of age. * The participant might have documented GAA enzyme deficiency from blood, skin, or muscle tissue. * The participant might be naïve to treatment with alglucosidase alfa. Exclusion Criteria: * The participant was cross-reactive immunologic material negative. * The participant required invasive ventilator support at the time of enrollment. * The participant had decompensated clinical heart failure. * The participant had a major congenital abnormality, excluding cardiac hypertrophy. * The participant had a clinically significant organ disease (excluding the signs and symptoms of Pompe disease). * The participant was currently receiving any investigational product. * The participant was participating in another clinical study. * The participant and/or the patient's parent/legal guardian was unable to adhere to the requirements of the study.